Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | HINT1 | P49773 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511836 | 1.00 | KDM4E (0.58) | KDM4EPOLA1TYMPTAS1R3TAS1R1 | |
| SCHEMBL3418302 | 1.00 | KDM4E (0.58) | KDM4EPOLA1TYMPTAS1R3TAS1R1 | |
| SCHEMBL3418307 | 1.00 | KDM4E (0.58) | KDM4EPOLA1TYMPTAS1R3TAS1R1 | |
| SCHEMBL22992716 | 0.90 | POLA1 (0.49) | KDM4EPOLA1TYMPTAS1R3TAS1R1 | |
| SCHEMBL8584063 | 0.89 | KDM4E (0.63) | KDM4EPOLA1TYMPTAS1R3TAS1R1 | |
| SCHEMBL22992490 | 0.86 | KDM4E (0.52) | KDM4EPOLA1TAS1R3TAS1R1PNP | |
| SCHEMBL13031161 | 0.86 | TYMP (0.53) | POLA1TYMPTAS1R3TAS1R1POLB | |
| SCHEMBL3635234 | 0.85 | KDM4E (0.59) | KDM4EPOLA1TYMPTAS1R3TAS1R1 | |
| SCHEMBL19666768 | 0.85 | KDM4E (0.71) | KDM4EPOLA1TYMPTAS1R3TAS1R1 | |
| SCHEMBL21828787 | 0.85 | KDM4E (0.71) | KDM4EPOLA1TYMPTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0754242-A4 | OLIGONUCLEOTIDE N3'-m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS INC (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | claimed |
| US-6169170-B1 | DUPLEX OLIGONUCLEOTIDE OF TWO COMPLEMENTARY STRANDS WHERE AT LEAST ONE STRAND HAS AT LEAST FIFTY PERCENT PHOSPHORAMIDATE LINKAGES AND AT LEAST TWO LINKAGES ARE CONSECUTIVE; ANTISENSE AGENTS WITH INCREASED PHOSPHODIESTERASE RESISTANCE | LYNX THERAPEUTICS, INC. | 2001-01-02 | — | — | US | disclosed |
| US-5965720-A | WITH SEQUENCE COMPLEMENTARY TO MESSENGER RNA FROM A GENE SELECTED FROM THE GROUP CONSISTING OF C-MYC, C-MYB, C-FOS, C-KIT, RAS AND BCR/ABL; ANTISENSE/ANTICARCINOGENIC AGENTS | LYNX THERAPEUTICS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5837835-A | STABILITY; HEAT RESISTANCE | LYNX THERAPEUTICS, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5726297-A | Oligodeoxyribonucleotide N3' P5' phosphoramidates | LYNX THERAPEUTICS, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0754242-A4 | OLIGONUCLEOTIDE N3'-m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| US-5631135-A | HYBRIDIZATION OF RIBONUCLEIC ACID TARGET; GENETIC ENGINEERING | LYNX THERAPEUTICS, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5599922-A | INHIBITOR TO SNAKE VENON PHOSPHODIESTERASE | LYNX THERAPEUTICS, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0754242-A1 | OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1997-01-22 | — | — | EP | disclosed |
| US-5591607-A | Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation | LYNX THERAPEUTICS, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1995025814-A1 | OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES | LYNX THERAPEUTICS, INC. (US) | 1995-09-28 | — | — | WO | disclosed |